How often is circulating SARS‑CoV‑2 spike protein detected in people with long‑COVID compared with recovered asymptomatic individuals?

1. What the best available cohorts report: a sizable signal in PASC

A clinical cohort study and subsequent syntheses have reported that a majority—on the order of half to two‑thirds—of people with long‑COVID have detectable SARS‑CoV‑2 antigens in plasma at some time point after acute illness; a news summary of a Clinical Infectious Diseases study states the spike antigen was most frequently detected in about 60% of PASC patients and that about 67% of PASC patients had at least one viral antigen present at some post‑acute time point ^{[1] [2]}.

2. What controls and recovered asymptomatic groups show: low, transient, or absent detection

By contrast, several reports and reviews indicate that recovered asymptomatic individuals and many acutely infected or vaccinated controls do not show persistent circulating spike beyond the expected early window, with some studies finding no spike in convalescent control plasmas while other small vaccine studies detected transient spike/S1 at low frequency after a first mRNA dose but not after booster doses ^{[4] [1] [2]}.

3. Why numbers differ so much: methods, timing and biological reservoirs

Detection frequency depends on assay sensitivity and target (full‑length spike, S1 subunit, nucleocapsid), specimen type (plasma, saliva, urine, tissue biopsy) and when samples were taken; ultrasensitive capture assays and magneto‑assays can reveal low‑level antigen that standard tests miss, and tissues such as gut epithelium can retain viral proteins long after nasopharyngeal clearance, creating intermittent release into circulation or packaging in extracellular vesicles that protect spike from rapid degradation ^{[5] [6] [3]}.

4. Biological interpretations and alternative explanations

Persistent circulating spike in PASC may reflect true viral reservoirs producing protein without productive systemic replication, release of antigen from damaged tissues, or spike carried in vesicles that evade rapid antibody removal — mechanisms discussed in multi‑omic and pathophysiology reviews that link antigen persistence to chronic inflammation, immune dysregulation and tissue‑specific pathology ^{[3] [7]}. Alternative possibilities include assay cross‑reactivity, antibody‑antigen complexing that alters detectability, or spike transiently present after vaccination in some individuals; observers caution that not every detection implies causation of symptoms and that findings are heterogeneous across cohorts ^{[5] [4] [8]}.

5. Limitations in the literature and what remains unsettled

Existing evidence is compelling but not definitive: many studies are small or convenience cohorts, assays are not standardized across groups, vaccination status and timing often confound interpretation, and longitudinal, well‑controlled studies that pair antigen detection with viral RNA, tissue biopsies and functional immune readouts are still needed to quantify how often circulating spike truly differentiates PASC from fully recovered asymptomatic people across populations ^{[7] [5] [4]}.

6. Bottom line for the question “how often?”

Conservatively summarized from current reporting, a substantial minority-to-majority of evaluated long‑COVID cohorts have detectable circulating spike or spike fragments — a frequently cited figure is about 60% in one PASC cohort — whereas recovered asymptomatic groups show low or transient detection in most studies; however, the exact prevalence varies widely by assay, sampling strategy and cohort, so the 60% figure should be understood as study‑specific rather than a universal truth ^{[1] [2] [3]}.